ESSA Pharma Inc.
| NASDAQ: EPIX | Healthcare / Biotechnology / Canada |
| 2.88 | -0.0600 | -2.04% | Vol 49.98K | 1Y Perf 66.10% |
| Oct 3rd, 2023 16:00 DELAYED |
| BID | 2.64 | ASK | 3.00 | ||
| Open | 2.94 | Previous Close | 2.94 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 21.60 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 650.00 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 39.36 | Earnings Rating | Strong Buy | |
| Market Cap | 127.01M | Earnings Date | 10th Aug 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.28 | |
| Beta | 2.06 |
Today's Price Range 2.652.94 | 52W Range 1.405.16 | 5 Year PE Ratio Range -5.20-1.70 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -11.18% | ||
| 1 Month | 0.68% | ||
| 3 Months | 8.89% | ||
| 6 Months | -0.68% | ||
| 1 Year | 66.10% | ||
| 3 Years | -55.11% | ||
| 5 Years | -12.50% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -30.59 | |||
ROE last 12 Months | -19.44 | |||
ROA (5Y Avg) | -7.16 | |||
ROA last 12 Months | -19.09 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -20.65 | |||
Return on invested Capital Q | -4.17 | |||
Return on invested Capital Y | -20.36 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.30 | ||||
| 0.71 | ||||
| - | ||||
| - | ||||
| -5.20 | ||||
| -0.65 | ||||
| 0.71 | ||||
| 3.79 | ||||
| -47 589 200.00 | ||||
| Forward PE | -3.09 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 72.40 | ||||
| 73.20 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -2 560.80 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.20 | -0.17 | 15.00 |
| Q02 2023 | -0.20 | -0.16 | 20.00 |
| Q01 2023 | -0.24 | -0.15 | 37.50 |
| Q04 2022 | -0.28 | -0.14 | 50.00 |
| Q03 2022 | -0.27 | -0.20 | 25.93 |
| Q02 2022 | -0.25 | -0.25 | 0.00 |
| Q01 2022 | -0.23 | -0.21 | 8.70 |
| Q04 2021 | -0.23 | -0.20 | 13.04 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.22 | 0.00 | - |
| 9/2023 FY | -0.71 | 5.33 | Positive |
| 12/2023 QR | -0.24 | 4.00 | Positive |
| 9/2024 FY | -1.00 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.20 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 49.98K |
| Shares Outstanding | 44.10K |
| Shares Float | 27.12M |
| Trades Count | 441 |
| Dollar Volume | 136.56K |
| Avg. Volume | 41.22K |
| Avg. Weekly Volume | 59.10K |
| Avg. Monthly Volume | 33.26K |
| Avg. Quarterly Volume | 31.29K |
ESSA Pharma Inc. (NASDAQ: EPIX) stock closed at 2.94 per share at the end of the most recent trading day (a -4.85% change compared to the prior day closing price) with a volume of 35.82K shares and market capitalization of 127.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. ESSA Pharma Inc. CEO is David R. Parkinson.
The one-year performance of ESSA Pharma Inc. stock is 66.1%, while year-to-date (YTD) performance is 16.67%. EPIX stock has a five-year performance of -12.5%. Its 52-week range is between 1.4 and 5.16, which gives EPIX stock a 52-week price range ratio of 39.36%
ESSA Pharma Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 0.71, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -19.09%, a ROC of -20.65% and a ROE of -19.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from ESSA Pharma Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. ESSA Pharma Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ESSA Pharma Inc. is Strong Buy (1), with a target price of $21.6, which is +650.00% compared to the current price. The earnings rating for ESSA Pharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ESSA Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ESSA Pharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 42.01, ATR14 : 0.26, CCI20 : 83.58, Chaikin Money Flow : 0.24, MACD : 0.04, Money Flow Index : 63.98, ROC : 1.38, RSI : 51.17, STOCH (14,3) : 49.32, STOCH RSI : 0.17, UO : 67.66, Williams %R : -50.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ESSA Pharma Inc. in the last 12-months were: David R. Parkinson (Buy at a value of $59 041), David Ross Parkinson (Buy at a value of $59 041), David S. Wood (Buy at a value of $21 585), David Wood (Buy at a value of $21 585), Franklin M. Berger (Sold 272 840 shares of value $729 052 )
ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
CEO: David R. Parkinson
Telephone: +1 778 331-0962
Address: 999 West Broadway Street, Vancouver V5Z 1K5, BC, CA
Number of employees: 25
